Misys Healthcare and Allscripts Announce Merger


By Neil Versel

March 18, 2008 | Misys Healthcare continued its extreme corporate makeover by announcing early Tuesday its intention to merge with ambulatory health-IT powerhouse Allscripts.

According to the merger agreement, Misys Healthcare’s London-based parent company, Misys plc, will offer full equity in the Raleigh, N.C.-based health care division plus $330 million in cash in exchange for a controlling, 54.5 percent stake in the combined company. In turn, Allscripts will pass the $330 million to its shareholders in the form of a special dividend, at the rate of approximately $4.90 per share, the two companies say.

The combined firm, tentatively called Allscripts-Misys, will exist as a yet-undetermined subsidiary of Allscripts and operate from the current Allscripts headquarters in Chicago. Most current Allscripts executives are keeping their jobs, though Misys plc chief Mike Lawrie will become executive chairman of the board of directors, and Misys will control six of 10 board seats, the two companies say.

“We’ve created today a clear leader in the clinical software, connectivity, and information space for physicians in the United States,” Allscripts chief executive Glen Tullman said in a video interview posted online this morning.

“We take Misys’ very strong position in practice management and we combine that with Allscripts’ undisputed leadership in clinical applications like electronic health records,” Lawrie added in the company-provided video. “This is one of the first times in the ambulatory space where we’re putting together two significant assets and really gaining the critical mass necessary to make a difference in how health care is delivered in the U.S.”

Together, Misys and Allscripts claim they will serve 150,000 U.S. physicians with their products, or about one-third of doctors practicing in non-inpatient environments. The customer base also includes 700 hospitals.

The companies say the merger will create $15 million to $20 million in pre-tax savings during the first full year after the deal closes, and $25 million to $30 million annually in subsequent years. Allscripts reported 2007 revenues of $282 million, while Misys Healthcare had $376 million in sales for the 12 months ended May 31, 2007, making the combined company a $658 million entity.

Both companies have struggled of late. Allscripts shares hit a 12-month low of $8.67 in intraday trading on the Nasdaq Monday, before closing at $8.76 on the Nasdaq, though the price has shot up more than 20 percent Tuesday morning on the merger news. Investors punished Allscripts last month for falling short of analysts’ expectations for 2007 income.

Misys Healthcare had a management shake-up little over a year ago in the wake of disappointing financial results for 2006.

Last summer, Misys Healthcare sold off its inpatient electronic medical records (EMR) and its diagnostics systems divisions in separate transactions valued at $414.5 million, leaving the company with three markets: physician office IT, home care, and health care claims management. (See “Misys Drops Two Business Divisions.”) Just last month, Misys made good on its promise to open the source code to its Misys Connect interoperability software. (See “Deals, Deployments, and Short News - Feb. 19, 2008.”)

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

This Bio•IT World Briefing On “Next-Generation Sequencing,” underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now



SGI's Meeting Today’s Computational Needs for Science
The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.

Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows. Download This Free Paper



SGI's Supercharging Proteomics Discovery
The deeper study of proteins and their interactions can reveal scientific information once considered nearly untouchable to scientists and researchers. Today, unprecedented advancements in computing power are enabling the creation of mounds of proteomic based data along with the accompanying bottlenecks data can create.

Rather than just “simplify the experiment” to fit the computational resources an alternative is now available with the SGI Proteomics Appliance. This complimentary white paper, produced by the Bio-IT World Custom Publishing Group, looks at ways to use the Proteomic Appliance to handle the most intensive proteomics computing tasks facing science today. Download This Free Paper



Life Science Webcasts & Podcasts

Waters

Automate Method SOPs for Greater Efficiency and Fewer Errors with Waters® NuGenesis® Intelligent Procedure Manager

The Waters® NuGenesis® SDMS Intelligent Procedure Manager is a workflow software package designed to guide the laboratory analyst through a routine, comprehensive method standard operating procedure (SOP) and integrate results with a chromatography data system. The Intelligent Procedure Manager addresses the predominately manual activities required to perform an analytical method or test, reducing cycle times up to 50-75% as compared to a traditional paper trail with fewer opportunities for human error. From late-stage development to final product quality control and lot release, Intelligent Procedure Manager can be applied to any lab environment where rigorous adherence to approved test methods and SOPs must be followed, including compliance requirements for cGMP operations. Download Now


More Podcasts

Job Openings

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD

Lilly Singapore Center for Drug Discovery (LSCDD) - Senior Software Engineer
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit: LSCDD

Related Resources & Products

Global Digital Healthcare 2006
Global Digital Healthcare 2006
Bio-IT World Briefing On: Boosting Productivity In Healthcare
Personalized Healthcare 2010



For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext 100 or via email to [email protected].